154-Spatial biomarkers of SHR-A1811 response

Paper Talk · Oct 21, 2025 · 15m

This article details a translational study that investigates the spatial determinants of the efficacy of the antibody-drug conjugate (ADC) SHR-A1811 in HER2-positive breast cancer patients receiving neoadjuvant treatment. The research integrates multi-omics data, including DNA/RNA sequencing and advanced spatial analysis techniques like computational pathology and Xenium in situ imaging. Key findings suggest that biomarkers predicting treatment response vary by hormone receptor (HR) status: HR-negative tumors respond better with high infiltration and tight interaction of cytotoxic T cells…